Compare ATRA & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRA | PDSB |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 37.5M |
| IPO Year | 2014 | 2015 |
| Metric | ATRA | PDSB |
|---|---|---|
| Price | $4.92 | $0.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | 307.4K | ★ 323.6K |
| Earning Date | 03-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 25.90 |
| EPS | ★ 2.57 | N/A |
| Revenue | ★ $120,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $0.52 |
| 52 Week High | $19.15 | $1.90 |
| Indicator | ATRA | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 33.05 |
| Support Level | $4.27 | N/A |
| Resistance Level | $5.80 | $1.16 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 7.70 | 13.66 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.